STEM -- StemCells, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc.

STEM 16.30

+5.2%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (352)	1/23/2000 1:48:00 PM
From: Edscharp	Read Replies (2) of 805

Marc, It's a small world. Nice to hear from you again. I've heard of Geron primarily because of their work on the aging process and not their work in stem cell technology, but I'll check out the link you provided. I do know that CytoTherapeutics is currently regarded as the leader in stem cell technology. This is from the Medical Technology Stock Letter - Dec 29, 1999: "We are going to reserve comment on CytoTherapeutics at this time. When we spoke with the company recently, their excitement about the promise of their stem cell technology programs was unmistakable. They also indicated that within the next couple of months, the reasons for their excitement would become much more concrete to the investment community. since the new management took over about two years ago, the company has been very conservative in creating visibility for the research they have been conducting. We trust management, however, and are confident that their promises to share more openly the progress at CTII are sincere. There is no question that stem cell technology is a potential blockbuster technology is a potential blockbuster technology. We are comfortable that CTII has the proper team in place to capitalize on this opportunity. Updates on the future direction of CTII will follow as we learn more. CTII is a buy under $2." Note, that this was published well before the recent news concerning brain stem cells. The only drawback to companies engaged in stem cell technology is that research still appears to be pre-clinical. The technology is compelling, but it'll be a long wait. Regards, Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next